BioCentury | Dec 31, 2020
Emerging Company Profile

Cardior: targeting microRNAs to treat heart failure

...oligonucleotide inhibitor of miR-132 to treat heart failure.miR-132...
...various forms or cardiac stress.“Once we block miR-132...
...fraction —should translate to humans well because miR-132...
BioCentury | Dec 17, 2020
Deals

Dec. 16 Quick Takes: MacroGenics' margetuximab approved for breast cancer; plus sotorasib, Mesoblast, Cardior, Takeda, Allero

...the antisense oligonucleotide, which inhibits the non-coding microRNA-132...
BioCentury | Oct 24, 2020
Translation in Brief

UNC Chapel Hill Angelman gene therapy rescues motor function; plus data backing planned Pacylex, Kronos clinical trials and more

...company, which published the data in the European Heart Journal, is evaluating the antisense oligonucleotide against miR-132...
...blastocyst-stage embryos developed from the two-cell embryo stage.TARGETSATXN3 – Ataxin 3 CDK9 – Cyclin dependent kinase 9 miR-132...
BioCentury | Feb 28, 2020
Distillery Therapeutics

An antisense oligo inhibitor of miR-132 for heart failure

...DISEASE CATEGORY: Cardiovascular INDICATION: Heart failure The miR-132 inhibitor CDR132L could treat heart failure. In pigs...
...Inc. (NASDAQ:RGLS) has the miR-132 inhibitor anti-miR-132 in preclinical testing for non-alcoholic steatohepatitis (NASH). TARGET/MARKER/PATHWAY: MicroRNA-132 (miR-132)...
BioCentury | Feb 1, 2020
Preclinical News

Cardior eyes heart failure cure with miRNA inhibitor

...cardiovascular diseases. Its lead candidate is CDR132L, a locked nucleic acid (LNA) antisense oligonucleotide against miR-132...
...other company, Regulus Therapeutics Inc. (NASDAQ:RGLS), is developing a miR-132 inhibitor. Its antisense oligonucleotide against miR-132...
...antisense oligonucleotide against miR-132 is in preclinical testing for non-alcoholic steatohepatitis (NASH). Targets: miR-132 - MicroRNA-132...
BioCentury | Apr 28, 2016
Finance

Public-Private Partnership Roundup

...and the company's pipeline includes four miRNA-based cancer therapeutics in preclinical development. In particular, microRNA-132 (miR-132)...
...patients. In December, the Laval group published a study demonstrating that deficiencies and deletions of miR-132...
...Korea University of Laval, Quebec City, Quebec Targets and Compounds miR-127 - microRNA-127 miR-132 - microRNA-132...
BioCentury | Aug 12, 2010
Distillery Therapeutics

Indication: Cancer

...status Publication and contact information Cancer Cancer MicroRNA-132 (miR-132) A study in mice suggests that inhibiting miR-132...
...mouse xenograft model of human breast cancer, vessel-targeted delivery of an antagomir against miR-132, called anti-miR-132...
Items per page:
1 - 7 of 7